washington  reuters    two u s  lawmakers are questioning whether heritage pharmaceuticals misled them in response to a  congressional inquiry about the rising price a common antibiotic  after  u s  states this week accused the company of price fixing  in a dec   letter to heritage seen by reuters  maryland democratic representative elijah cummings and vermont independent senator bernie sanders said they feared the company was  disingenuous at best  in october  when it told them it had not seen any significant price increases for its doxycycline hyclate product   we are very concerned that you made these assertions to congress on behalf of heritage during the exact time period that its executives were engaged in a price fixing scheme to prevent competition from driving down prices of doxycycline hyclate   they wrote  in response to friday s letter  the company said it does not make the same version of doxycycline hyclate that the lawmakers asked about in   heritage makes a delayed release version  not the immediate release version that was the subject of the  inquiry  heritage said it explained this to the lawmakers in its  response  the letter to heritage comes after criminal and civil charges were filed by the justice department and  states in connection with an alleged price fixing scheme involving doxycycline hyclate and glyburide  a diabetes drug  on wednesday  the justice department criminally charged heritage s former chief executive officer jeffrey glazer and former heritage vice president of commercial operations jason malek  accusing them of colluding with other generic manufacturers in schemes that entailed allocating market share and conspiring to raise prices  the next day   states filed a parallel civil lawsuit against heritage  along with mylan nv  teva pharmaceuticals  mayne pharma group  citron pharma and aurobindo pharma ltd   saying they colluded to fix prices  the lawsuit characterized heritage as the  ringleader   with glazer and malek overseeing and running the scheme  mylan and teva have previously denied the states  civil charges  sanders and cummings launched a congressional inquiry into rising generic drug prices on oct      including the price of doxycycline hyclate   as part of that  they sent a letter to glazer while he was still ceo of heritage to inquire about the prices  gary ruckelshaus  who was then heritage s outside counsel and now serves as vice president and general counsel  responded later that month and said heritage  has not seen any significant price increases  for the drug  